Rockville, Md. (February 13, 2023) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, today, is proud to announce the publication of “In Vitro Treatment of Extracorporeal Membrane Oxygenation (ECMO) Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets” in the Journal of Cardiothoracic and Vascular Anesthesia.
"This pilot study continues our investigation of promising clinical settings where Thrombosomes® can potentially add to the standard of care, in this case under conditions where extracorporeal circuits impair endogenous platelet function," said Dr. Keith Moskowitz, Vice President of Discovery Research.
“Hemostasis during ECMO requires vigilance and ready interventions. We will continue to study Thrombosomes’® ability to address mechanical circulatory assist-related bleeding,” said Dr. Allan Alexander, Chief Medical Officer.
"This is an important milestone for the company on the road to achieving our mission of saving lives with our cellular therapeutics,” said Mike Gaffney, Cellphire Therapeutics CEO. “We appreciate and thank our collaborators, federal funding agencies, and our team for helping us realize this achievement.”
Full article can be found HERE.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.Cellphire.com.
Media and Investor Relations
Director, Business Operations